Orion
52,44
EUR
-0,23 %
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
13.917 følger denne virksomhed
-0,23%
+7,35%
+22,58%
+17,58%
+12,9%
+34,67%
+16,69%
+36,38%
+366,96%
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Læs mereMarkedsværdi
7,4 mia. EUR
Aktieomsætning
7,27 mio. EUR
P/E (adj.) (24e)
22,38
EV/EBIT (adj.) (24e)
17,69
P/B (24e)
7,43
EV/S (24e)
4,78
Udbytteafkast, % (24e)
3,15 %
Omsætning og EBIT-margin
Omsætning mia.
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Finanskalender
25.2
2025
Årsrapport '24
3.4
2025
Generalforsamling '25
23.4
2025
Delårsrapport Q1'25
Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Save the Date: Orion’s Capital Markets Day on 22 May 2025

Orion, Webcast with teleconference, Q4'24
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025
Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting
Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide
Orion and Marinus terminate agreement for ganaxolone in Europe
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Drug development investment: Value creation through M&As and licensing agreements
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
